Quick Answer
Viking Therapeutics, Inc. reported Earnings Per Share Diluted of $3.19 (loss) per share for the year ending 2025.
- Viking Therapeutics, Inc. showed a decrease of -215.8% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Viking Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 11, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $0.23 (loss) per share | Q1 2018: $0.10 (loss) per share | Q1 2019: $0.07 (loss) per share | Q2 2021: $0.20 (loss) per share | Q3 2021: $0.17 (loss) per share | Q1 2022: $0.21 (loss) per share | Q2 2022: $0.23 (loss) per share | Q3 2022: $0.21 (loss) per share | Q1 2023: $0.25 (loss) per share | Q2 2023: $0.19 (loss) per share | Q3 2023: $0.23 (loss) per share | Q1 2024: $0.26 (loss) per share | Q2 2024: $0.20 (loss) per share | Q3 2024: $0.22 (loss) per share | Q1 2025: $0.41 (loss) per share | Q2 2025: $0.58 (loss) per share | Q3 2025: $0.81 (loss) per share.
- Over the full 5 years of available data (2021 to 2025), Viking Therapeutics, Inc.'s Earnings Per Share Diluted has declined by 349.3%.
- Historical annual values: Fiscal year 2025: $3.19 (loss) per share | Fiscal year 2024: $1.01 (loss) per share | Fiscal year 2023: $0.91 (loss) per share | Fiscal year 2022: $0.90 (loss) per share | Fiscal year 2021: $0.71 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: